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PURPOSE. To assess the occurrence and the disease expression of the common p.Asn1868Ile
variant in patients with Stargardt disease (STGD1) harboring known, monoallelic causal
ABCA4 variants.
METHODS. The coding and noncoding regions of ABCA4 were sequenced in 67 and 63 STGD1
probands respectively, harboring monoallelic ABCA4 variants. In case p.Asn1868Ile was
detected, segregation analysis was performed whenever possible. Probands and affected
siblings harboring p.Asn1868Ile without additional variants in cis were clinically evaluated
retrospectively. Two asymptomatic siblings carrying the same ABCA4 variants as their
probands were clinically examined. The penetrance of p.Asn1868Ile was calculated using
allele frequency data of ABCA4 variants in non-Finnish European individuals.
RESULTS. The p.Asn1868Ile variant was found in cis with known variants in 14/67 probands. In
27/67 probands, we identified p.Asn1868Ile without additional variants in cis, in combination
with known, mainly severe ABCA4 variants. In 23/27 probands, the trans configuration was
established. Among 27 probands and 6/7 STGD1 siblings carrying p.Asn1868Ile, 42%
manifested late-onset disease (>44 years). We additionally identified four asymptomatic
relatives carrying a combination of a severe variant and p.Asn1868Ile; ophthalmologic
examination in two persons did not reveal STGD1. Based on ABCA4 allele frequency data, we
conservatively estimated the penetrance of p.Asn1868Ile, when present in trans with a severe
variant, to be below 5%.
CONCLUSIONS. A significant fraction of genetically unexplained STGD1 cases carries
p.Asn1868Ile as a second variant. Our findings suggest exceptional differences in disease
expression or even nonpenetrance of this ABCA4 variant, pointing toward an important role
for genetic or environmental modifiers in STGD1.
Keywords: ABCA4 protein, nonpenetrance, modifiers, Stargardt disease, retinal dystrophy
Autosomal recessive Stargardt disease (STGD1; MendelianInheritance in Man [MIM] 248200) represents the most
common hereditary macular dystrophy (estimated prevalence,
1:10,000)1 and is funduscopically characterized by lipofuscin
deposits in the retinal pigment epithelium (RPE), presenting as
yellow-white flecks and progressive atrophy of the macular
RPE.2,3 STGD1 is caused by sequence variants in the
transmembrane ATP-binding cassette transporter type A4
(ABCA4; MIM 601691).4 Different combinations of ABCA4
variants give rise to several phenotypes, which can partly be
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attributed to differences in the residual activity of the ABCA4
protein.5–10 A combination of disease-causing ABCA4 alleles
may, therefore, result in a severe, early-onset STGD1 pheno-
type (i.e., onset 10 years of age),11,12 which is often observed
as rapidly progressive cone-rod dystrophy,5,13 in classical
STGD1,10 or in late-onset STGD1.14–16 In about half of the
patients with late-onset STGD1 (onset >44 years of age), only
one disease-causing allele was identified, despite the sequence
analysis of all coding variants.16
In carriers of monoallelic ABCA4 variants, the second
variant can reside in introns, outside of splice sites, not
detected by standard sequencing methods.17–20 A very small
fraction of these unidentified defects comprise copy number
variants that elude detection by PCR-based sequencing
techniques.18,21–23 Identification of disease-causing alleles and
insight into their associations with differences in disease
presentation and severity are essential for the counseling of
patients and become increasingly important, as research on
therapeutic approaches is rapidly evolving.
Recently, a frequent ABCA4 coding variant, c.5603A>T
(p.Asn1868Ile), which thus far was considered benign due to
its high minor allele frequency (AF) of 6.6% in the non-Finnish
European population,24 was associated with STGD1.25,26 This
variant was found to be phenotypically expressed only when in
trans with a deleterious mutation (i.e., presence of the variants
on different alleles) and explained >50% of all monoallelic
cases and ~80% of late-onset cases in a US cohort.26 In
addition, the c.2588G>C (p.[Gly863Ala, Gly863del]) variant
was proposed to act as a mild pathogenic variant only when in
cis with p.Asn1868Ile (i.e., presence of the variants on the
same allele).
In this study, we investigated STGD1 probands with a
single disease-causing ABCA4 allele for the presence of the
p.Asn1868Ile variant, performed segregation analysis
through the inclusion of unaffected family members to
assess the configuration of the identified ABCA4 variants
(i.e., in cis or in trans), and performed ophthalmologic
studies to evaluate the full spectrum of phenotypes
associated with the single-variant allele p.Asn1868Ile (i.e.,
no ABCA4 variants identified in cis). In addition, we
calculated the penetrance for the p.Asn1868Ile variant by
using allele frequencies of severe ABCA4 variants.
METHODS
Study Population and Genetic Analysis
We ascertained 67 clinically suspected STGD1 patients in
whom only one disease-causing variant in the ABCA4 gene had
been identified, from eight ophthalmic centers in The Nether-
lands (n ¼ 64) and one center in Germany (n ¼ 3). Between
1998 and 2017, these subjects were screened for disease-
causing variants in the coding regions and flanking splice sites
of ABCA4, and, recently, for 63 subjects, ~95% of the entire
ABCA4 gene (exons and introns) was further sequenced by
using a custom Haloplex Target Enrichment kit (Agilent, Santa
Clara, CA, USA) as described previously.27 All variants identified
by Haloplex-based ABCA4 sequencing were confirmed using
Sanger sequencing. We investigated probands harboring
monoallelic variants for the presence of the p.Asn1868Ile
variant and rare (minor AF <0.005) deep-intronic variants. Four
DNA samples were analyzed using non-Haloplex-based alterna-
tive techniques (Supplementary Methods S1).
The segregation of the sequence variants identified in the
probands was studied by sequencing the corresponding
genomic DNA fragments in relatives (Supplementary Table
S1). Participants gave informed consent after an explanation of
the nature of the study. The study procedures were performed
according to approval of the medical ethics committee of the
Radboud University Medical Center and the tenets of the
Declaration of Helsinki.
Clinical Evaluation
Probands and affected siblings carrying the single-variant
allele p.Asn1868Ile were clinically evaluated. Medical re-
cords were reviewed and available clinical data were
collected, comprising age at onset and initial symptoms,
age at diagnosis, best-corrected visual acuity (BCVA), and
findings on ophthalmoscopy. Age of onset was defined as the
age at which the initial symptoms were noted by the patient.
In asymptomatic subjects and in cases where age at onset
was not noted in the patient file, we used the age at which
macular abnormalities were first diagnosed by an ophthal-
mologist.
Furthermore, we examined available data acquired by
fundus photography, fundus autofluorescence (FAF) imaging
using a confocal scanning laser ophthalmoscope (Spectralis;
Heidelberg Engineering, Heidelberg, Germany), spectral
domain-optical coherence tomography (OCT; Spectralis), or
time-domain OCT (Stratus; Carl Zeiss Meditec, Dublin, CA,
USA), fluorescein angiography, and full-field electroretino-
graphy, according to the International Society for Clinical
Electrophysiology of Vision standards. We assessed presence
of foveal sparing, which we defined as RPE atrophy
encircling a structurally and functionally (BCVA, ‡20/200)
preserved fovea by ‡1808,15 by evaluation of FAF and/or
OCT.
Two asymptomatic siblings who carried the same combi-
nation of ABCA4 variants as the respective probands were
clinically examined by measurement of BCVA and performance
of fundus photography, FAF, and OCT.
ABCA4 Allele Frequency Calculations and
p.Asn1868Ile Penetrance Estimates
To assess the penetrance of the common variant p.Asn1868Ile
when present in trans with a severe ABCA4 variant, we used
AF data in ~33,000 non-Finnish European control subjects in
Exome Aggregation Consortium24 (available at: http://exac.
broadinstitute.org; accessed September 01, 2017), as at least
24/27 patients belong to this population. First, because we did
not know all ABCA4 variants that are in linkage disequilibrium
with p.Asn1868Ile, we estimated the frequency of the single-
variant allele p.Asn1868Ile. Zernant et al.26 indicated that 10%
of c.2588G>C alleles carry c.5603A>T (p.Asn1868Ile) in cis
and that this allele, containing both variants, probably acts as a
fully penetrant mild allele if present in a compound
heterozygous state with a severe ABCA4 variant. In the same
study, consistent with our data, the frequent noncanonical
splice site variant c.5461-10T>C was always found in cis with
c.5603A>T (p.Asn1868Ile). Therefore, the AF of the single-
variant allele p.Asn1868Ile was calculated based on its total AF
minus the AF of c.5461-10T>C and 10% of the AF of
c.2588G>C. Other variants have been found in cis with
p.Asn1868Ile, but their cumulative non-Finnish European AF is
likely negligible and was not taken into account.
Second, we calculated a cumulative AF of severe ABCA4
variants. We determined the sum AF of all protein-truncating
variants (i.e., stop mutations, frameshift mutations) and
canonical splice site variants that, in the majority of cases,
result in exon skipping and likely in the absence of ABCA4
activity, and added the AF of noncanonical splice site variants
(i.e., RNA splice variants outside the conserved intronic
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dinucleotides at the ends of introns) that resulted in less than
25% of normally spliced ABCA4.28
Finally, given an estimated prevalence of STGD1 of 1 in
10,000 individuals1 and a population in The Netherlands of
17,150,000 people, the expected and observed number of
STGD1 patients due to the combination of the single-variant
allele p.Asn1868Ile and a severe variant in The Netherlands
were compared.
RESULTS
Genetic Analysis
In 14/67 probands, we found p.Asn1868Ile to be in cis with
causal protein-coding or splice site variants, that is c.5461-
10T>C (n ¼ 9), c.2588G>C (n ¼ 3), c.4469G>A (n ¼ 1), and
c.818G>A (n ¼ 1). We excluded these patients from clinical
evaluation.
FIGURE 1. ABCA4 variant c.5603A>T (V1) is associated with variable age at onset and putative nonpenetrance of Stargardt disease. (A) Segregation
analysis of ABCA4 variants in STGD1 families A–D, and G, with multiple affected individuals, showed that V1 in combination with a severe variant
segregated with the disease. As expected for an autosomal recessive-inherited Mendelian trait, all affected and genetically tested individuals in
families A–D, and G carry two ABCA4 variants in trans, whereas unaffected individuals carry one or no variant. (B) In families E, F, and H, reduced
penetrance or even nonpenetrance occurs. Family H is part of a previously described multigeneration pedigree.13,20 Proband H-II:3 and the
unaffected sibling H-II:1 carry V1 and c.2919-?_3328þ?del, whereas the unaffected individual H-II:2, the spouse of H-II:1, is compound heterozygous
for V1 and c.[5461-10T>C; 5603A>T]. For H-I:1, the variants were deduced by haplotype analysis.
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In 27/67 probands, we detected the single-variant allele
p.Asn1868Ile; in 23 patients, we could establish the trans
configuration of the identified variants (Figs. 1A, 1B; Supple-
mentary Figs. S1, S2), either due to segregation analysis (n ¼
21) or because the p.Asn1868Ile variant was found in a
homozygous state (Y-II:1 and AA-II:1). In the remaining four
probands (K-II:1, N-II:1, R-II:1, and Z-II:1), segregation analysis
could not be completed due to the absence of DNA of relatives
(Table, footnote #; Supplementary Fig. S2). Additionally, in
probands I-II:3, J-II:2, Y-II:1, and AA-II:1, we could not exclude
the presence of intronic variants in cis with p.Asn1868Ile, as
the noncoding regions of ABCA4 in these individuals were not
sequenced.
Among the 27 probands harboring the single-variant allele
p.Asn1868Ile, 19 carried p.Asn1868Ile together with a protein-
truncating mutation due to a stop (n¼ 4), a frameshift (n¼ 4),
a canonical splice site variant (n ¼ 1), or because of
noncanonical splice site variants elsewhere shown to result
in protein truncations (n ¼ 10) (Table).27,28 The remaining
eight probands harbored seven unique variants: six missense
variants and one noncanonical splice site variant
(c.5714þ5G>A) that has a moderately severe effect on
splicing.28 Among these missense variants, p.Gly1961Glu in
the vast majority of STGD1 cases acts as a mild variant,26,29,30
whereas p.Phe608Ile is considered a severe variant.31 For the
remaining missense variants (p.Glu1087Lys, p.Cys1488Arg,
p.Gly1972Arg, and p.Met2143Arg), the effect on protein
function is unclear.
Segregation analysis in 10 siblings affected by STGD1
identified 7 individuals who harbored the same causal variants
as the respective probands (Fig. 1A). In two families, we found
affected siblings carrying different combinations of disease-
causing ABCA4 alleles (Supplementary Fig. S1).
Clinical Evaluation
Thirty-four STGD1 patients (27 probands and 7 siblings) that
harbor p.Asn1868Ile in combination with a known causal
variant were identified, 12 of whom were male and 22 were
female. Detailed clinical characteristics of 32/34 subjects
carrying p.Asn1868Ile are depicted in the Table. For two
individuals, detailed clinical data were not available (A-II:2 and,
besides age at onset, A-II:1; Figure 1A).
None of the subjects manifested early-onset STGD1 (age at
onset, 10 years). Fourteen patients showed late-onset STGD1
(age at onset, >44 years), and 19 subjects manifested classical
STGD1 (age at onset, 11–44 years). The mean age of onset was
42 years (SD, 16 years), with the majority of patients
presenting with decreased visual acuity. Other initial symptoms
included scotoma and metamorphopsia. Patients D-II:3, R-II:1,
and U-II:1 did not experience visual symptoms at the time of
diagnosis at the age of 52, 30, and 37 years, respectively; all
three manifested few flecks, largely confined to the macular
region, and a perifoveal ring of RPE atrophy with a relatively
spared fovea.
Classical STGD1, in the majority of patients (14/19), was
characterized by early involvement of the macula featuring
flecks, beaten bronze atrophy, and/or mottled decreased FAF,
all largely confined to the macular and perimacular region. In
the minority of patients (5/19), flecks throughout the posterior
pole were observed, accompanied by pronounced atrophy in
the posterior pole and midperiphery in 4/5 patients. The latter
combination of fundus characteristics might represent a later
disease stage, because available data of the first decade(s) after
disease onset for the four patients manifesting atrophy (B-II:3, I-
II:3, G-II:4, and T-II:1) were insufficient to assess fundus
characteristics early in the disease. However, in 1/5 patients (C-
II:1, with an age at onset of 41 years), flecks throughout the
posterior pole and midperiphery with parafoveal atrophy were
observed in the year after he first experienced symptoms,
suggesting either slowly progressive disease that the patient
himself had long been unaware of, or a different subpheno-
type. Foveal sparing in the classical STGD1 group was
observed in 5/19 patients (age at onset, 27–41 years) (Table).
Late-onset STGD1, in the majority of clinically evaluated
patients (8/13), was characterized by flecks throughout the
posterior pole and midperiphery, often followed by sharply
demarcated atrophy. Yet, three patients (E-II:3, J-II:2, and Y-II:1,
with an age at onset of 56, 56, and 47, respectively) showed
early exclusive involvement of the macula with perimacular
flecks and macular beaten bronze atrophy and/or macular
mottled decreased FAF, which are characteristics that were
observed in the majority of the classical STGD1 patients. The
remaining two patients showed both flecks throughout the
posterior pole and midperiphery as well as mottled, decreased
FAF in the macula at first presentation. RPE atrophy in a foveal
sparing pattern was observed in 9/13 subjects, whereas 2/13
patients did not show macular atrophy yet.
In two late-onset STGD1 patients (G-II:1 and G-II:2), who
were initially diagnosed with age-related macular degeneration
(AMD) at the age of 72 and 69, respectively, flecks appeared
absent, as assessed by ophthalmoscopy and fundus photogra-
phy. Yet, they did exhibit widespread hypo- and hyperauto-
fluorescent flecks on FAF (Fig. 2), highlighting the clinical
value of FAF in the differentiation between AMD and late-onset
STGD1.
Variable Age at Onset and Incomplete Penetrance
When comparing affected siblings who harbor p.Asn1868Ile
(Fig. 1A), we observed fairly constant ages at onset in families
A, C, and D, whereas in family B, the age at onset between
FIGURE 2. Retinal imaging of a patient with a very late onset of STGD1. (A) Fundus photography showed no signs of flecks in patient G-II:2 at the
age of 72, 3 years after disease onset. (B, C) FAF performed in the same patient, at the same time, showed widespread hypo- and
hyperautofluorescent lesions. FAF and OCT showed perifoveal chorioretinal atrophy with foveal sparing.
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affected siblings varied tremendously (19 and 54 years of age).
In addition to STGD1, B-II:3 suffered from Coats-like exudative
vasculopathy, but this was first observed at the age of 57 and
affected only the right eye.
Surprisingly, we found three asymptomatic male siblings (E-
II:1, F-II:1, and H-II:1) in three STGD1 families that carried the
same compound heterozygous variants as their probands (Fig.
1B). Also, unaffected person H-II:2 carried an ABCA4 allele
with a severe variant (c.[5461-10T>C; 5603A>T]) and
c.5603A>T (p.Asn1868Ile) on the other allele. For asymptom-
atic siblings E-II:1 and H-II:1, in view of the large gap between
their current age and the age at onset of the proband, it is
plausible that they remain unaffected and can be considered
nonpenetrant. Moreover, current manifestation of STGD1 in E-
II:1 was excluded during ophthalmologic examination: fundus
photography, FAF, and OCT of E-II:1 showed no STGD1
phenotype at the age of 70, when his BCVA was 20/25 in the
right eye and 20/20 in the left eye (Figs. 3A–C). His sibling E-
II:3 reported initial symptoms at the age of 56 and was
diagnosed with STGD1 at the age of 59 (Figs. 3D–F). Although
the third asymptomatic sibling F-II:1 may develop STGD1 later
in life considering his current age and the age of onset of the
FIGURE 3. Retinal imaging of two sibling pairs in which an affected and an unaffected sibling harbor the same combination of ABCA4 variants. (A–
C) Asymptomatic sibling E-II:1 does not manifest STGD1 as assessed by fundus photography, FAF, and OCT at the age of 70 years. Fundus
photography shows one small yellow-white, round lesion, which appears hyperautofluorescent on FAF and is visible as a single subretinal deposit
on OCT. (D–F) Patient E-II:3 shows perimacular and peripapillary irregular yellow-white flecks on fundus photography at the age of 64. FAF reveals
hyperautofluorescent lesions corresponding with the flecks and mottled decreased autofluorescence in the macula. OCT shows macular RPE
atrophy. (G–I) Asymptomatic sibling F-II:1 shows no abnormalities on fundus photography, FAF, and OCT at the age of 47 years. (J–L) Patient F-II:2
shows foveal changes with perimacular and peripapillary irregular yellow-white flecks, mottled decreased FAF in the macula, and central RPE
atrophy at the age of 41 years, 9 years after disease onset.
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proband, he also underwent ophthalmologic examination,
which excluded current manifestations of STGD1. His fundus
photography, FAF, and OCT showed no abnormalities at the age
of 47, and BCVA was 20/20 in both eyes (Figs. 3G–I). His
sibling F-II:2 reported initial symptoms at the age of 32 and was
diagnosed with STGD1 at the age of 38 (Figs. 3J–L). The
asymptomatic cases in family H were not clinically examined,
so current manifestations of mild STGD1 phenotypes could not
be excluded.
Individuals harboring an ABCA4 variant that had been
designated as severe did not show STGD1 phenotypes more
often or more severe compared to individuals who harbored a
variant with mild, moderately severe, or unknown effect
(Table), with regard to age at onset or occurrence of foveal
sparing.
p.Asn1868Ile Shows a Very Low Penetrance in the
Caucasian Population
Based on previous findings26 and the results of this study, we
can conclude that p.Asn1868Ile represents a mild ABCA4
variant that in the majority of cases only results in STGD1
when present in trans with a severe ABCA4 variant.
First, the maximum AF of the single-variant allele
p.Asn1868Ile among ~66,000 non-Finnish European control
alleles, based on its total AF minus the AF of c.5461-10T>C and
10% of the AF of c.2588G>C, was 0.0645 (Fig. 4A).
Second, the total AF of severe ABCA4 variants (protein-
truncating variants and noncanonical splice site variants
determined to have a severe effect28) was 0.00271 (Fig. 4B),
which yielded an estimated prevalence of individuals with one
severe ABCA4 variant and p.Asn1868Ile of 0.000349 (Fig. 4C).
Given a total population in the Netherlands of 17,150,000
persons, the theoretical number of STGD1 cases with a severe
variant and p.Asn1868Ile thereby is 5991.
Third, the prevalence of STGD1 is estimated at 1 in 10,000
individuals,1 and in the Nijmegen STGD1 cohort, STGD1 due to
a severe ABCA4 variant and p.Asn1868Ile was observed in 25/
300 (8.3%) probands (Fig. 4D). Given a total population in The
Netherlands of 17,150,000 people, STGD1 due to this
combination of variants was expected in ~143 persons. If
the non-Finnish European AF are comparable to those in The
Netherlands, we concluded that the penetrance of the single-
variant allele p.Asn1868Ile, when present in combination with
a severe ABCA4 variant, was 2.4% (Fig. 4E).
As these calculations were based on a few assumptions, we
also calculated the penetrance based on alternative assump-
tions regarding the prevalence of STGD1 and the frequency of
severe ABCA4 variants (Supplementary Results S2). When
uncertainties in these factors of the calculation were taken into
account and in the unlikely situation that the alternative
assumptions would act in concert, the penetrance of
p.Asn1868Ile ranged between 0.24% and 9.54%.
DISCUSSION
By combining ABCA4 sequence analysis and segregation
analysis of the identified variants, we detected the common
variant p.Asn1868Ile as the second allele in 40% of cases
carrying monoallelic variants in our genetically unexplained
FIGURE 4. Penetrance calculation for c.5603A>T when in trans with severe ABCA4 variants. *Assuming complete linkage disequilibrium between
c.5603A>T and c.5641-10T>C based on this study and a previously published report.26 †Based on the observation that in an AMD cohort, 10% of
individuals with c.2588G>C also carry c.5603A>T.26 ‡Based on in vitro splice assays of non-canonical splice site variants.28
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STGD1 cohort. In the majority of the cases, p.Asn1868Ile was
found in trans with severe ABCA4 variants, thus pointing
toward the mild nature of this exonic variant in STGD1. In
agreement with a previous study,26 we found that a high
proportion of these p.Asn1868Ile carriers manifest the late-
onset STGD1 phenotype. However, among our cases, age at
onset was highly variable. Strikingly, we identified one
asymptomatic sibling and two unaffected siblings, all of whom
carried the same combination of ABCA4 variants as the
respective probands. The very low calculated penetrance of
p.Asn1868Ile of 2.4% in addition to the observed variability in
age at onset and phenotypes among individuals carrying the
same combinations of ABCA4 variants, lead us to hypothesize
that cis- or trans-acting genetic modifiers or environmental
factors greatly influence ABCA4 gene expression and, thereby,
the clinical presentation of STGD1.
As yet, very little is known about the potential nature, role,
and mechanisms of modifiers in STGD1. One group studied
gene expression variation in the human retina and found that
ABCA4 showed 1.5-fold higher expression in males compared
to females.32 Males carrying a high-expressed mild ABCA4
allele, thereby, may be less prone to develop STGD1. In our
study, we also observed an overrepresentation of females (22/
34, 65%) among patients carrying p.Asn1868Ile (one-sample
one-sided binomial test, P ¼ 0.0615). Furthermore, all three
putative nonpenetrant siblings are male. Further research is
needed to identify possible modifiers, explain the mechanisms
whereby they modify gene expression, and, most interestingly,
explore their potential as therapeutic targets.
Clinical overlap with other macular diseases, along with
inconclusive results of genetic analyses, can make the diagnosis
of late-onset STGD1 particularly challenging, as illustrated by
cases G-II:1 and G-II:2 who first experienced symptoms at the
age of 72 and 69, respectively. FAF and genetic analysis in these
cases were valuable in distinguishing late-onset STGD1 from
AMD. The identification of the second disease-causing allele,
whereby a significant fraction of late-onset STGD1 cases is now
genetically explained, strengthens the assumption that late-
onset STGD1 represents a distinct disease entity that should
not be confused with AMD.26 An accurate diagnosis is essential
for appropriate counseling of patients regarding prognosis and
heritability, and is relevant for putative therapies, for example
either recommendation or dissuading of vitamin A supplement
use in AMD and STGD1, respectively. Moreover, several
therapeutic trials in STGD1 patients are ongoing (http://
www.clinicaltrials.gov, last accessed 21-03-2018), requiring
identification of both disease-causing ABCA4 alleles.
The assessment of nonpenetrance has a few limitations.
First, this study showed that age at onset, which constitutes a
rather subjective measure, can vary tremendously even among
siblings carrying the same ABCA4 variants. Therefore, non-
penetrance cannot easily be confirmed by clinical examination
of unaffected persons carrying bi-allelic disease-causing ABCA4
variants. Regardless of whether the currently unaffected
subjects develop STGD1 later in life, a highly variable disease
expression was observed that raises new questions about the
disease mechanisms.
Second, although we have experimentally proven the
veracity of a nonpenetrance phenomenon, we are conscious
of the fact that nonpenetrance estimates cannot be considered
as definitive. Most importantly, late-onset STGD1 currently may
be underdiagnosed or misdiagnosed due to the clinical overlap
with AMD. In an AMD cohort (n¼698) from the Radboudumc,
The Netherlands, we however did not observe persons with a
combination of a severe ABCA4 variant and p.Asn1868Ile,
suggesting that misdiagnosis cannot be a major factor in
centers of clinical expertise on STGD1. Moreover, because
several nontruncating ABCA4 variants might also behave like
severe variants, our estimate of the cumulative AF of severe
variants in the population may in fact be higher, which would
make the resultant penetrance estimate (2.4%) even lower.
CONCLUSIONS
Identification of genetic variants underlying STGD1 is essential
to provide accurate counseling to patients and relatives and to
drive therapeutic approaches. A significant proportion of
STGD1 patients carries p.Asn1868Ile, which is associated with
late-onset STGD1 and a variable disease expression. In line
with these findings, we calculated an exceptionally low
penetrance of the p.Asn1868Ile variant, which may be
explained by the action of cis- or trans-acting genetic modifiers
or nongenetic factors in STGD1.
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